Oral PTH Shows Promise for Osteoporosis in Early Phase 2 Study
An investigational oral form of parathyroid hormone (PTH 1-34), EB 613 (Entera Bio Ltd) met its primary efficacy outcome in […]
A recent study published in the European Journal of Health Economics finds that the initiation of potentially inappropriate medication (PIM) […]fractures
Potentially inappropriate medication associated with a higher risk of fractures and mortality